News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Razan Mohty: Cellular therapies for acute leukemia – A Deep Dive from ASH24
Razan Mohty/X
Jan 4, 2025, 06:44

Razan Mohty: Cellular therapies for acute leukemia – A Deep Dive from ASH24

Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X:

“Cellular therapies for acute leukemia: A Deep Dive from ASH24.

Feel free to add any other relevant abstract.

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

1. “85 Engineering Myeloid Hematopoiesis By Nonviral Chimeric Antigen Receptor Knock-in to CD33 Enhances T Cell Infiltration in the Tumor Microenvironment”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

2. “369 Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

3. “371 Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

4. “372 Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

5. “2070 CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

6. “2076 CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

7. “3444 Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

8. “2071 Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

9. “4841 Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

10. “1433 Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

11. “4200 NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

12. “965 Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

13. “2810 Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

14. “4845 Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

15. “3458 Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

16. “963 Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

17. “2078 Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

18. “4197 Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

19. “3450 WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

20. “4830 CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

21. “4838 BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells”

Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24

More posts featuring Razan Mohty.

acute leukemia Acute Myeloid Leukaemia AML ASH24 cancer Cellular Therapy OncoDaily Oncology Razan Mohty T-ALL T-cell acute lymphoblastic leukemia
Special Coverage
Voices
Sep 5, 2025, 12:59
Fabio Ynoe de Moraes: Two Very Different Stories are Emerging About AI in Research
Insight
Sep 5, 2025, 12:58
Gianluca Franceschini: Inside the Integrated Breast Center of Gemelli Polyclinic
Voices
Sep 5, 2025, 12:51
How a Clinical Trial Gave Molly a Second Chance at Life - Conquer Cancer, the ASCO Foundation
Insight
Sep 5, 2025, 12:31
Courtney Jones: A New Publication From the Lab in Blood
Voices
Sep 5, 2025, 12:12
Jennifer Sullivan: Bringing "The Best of What We Are Wherever You Are"
Voices
Sep 5, 2025, 12:06
Armando Orlandi: Extraordinary Success for the 17th Breast Club!
Voices
Sep 5, 2025, 11:58
Roupen Odabashian: How WorkDone Health Tackles a $125B Healthcare Problem
Insight
Sep 5, 2025, 11:56
Eric Small on FY26 Budget: Saving Research Means Saving Lives
Voices
Sep 5, 2025, 11:45
Annalice Gandini: A Case Report on the Successful Use of Dual EGFR Blockade
Voices
Sep 5, 2025, 11:43
Conquering Underfunded and Rare Cancers Through Research - Conquer Cancer, the ASCO Foundation
Science
Sep 5, 2025, 11:34
Harpreet Singh: FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC
Voices
Sep 5, 2025, 11:26
Jia (Jenny) Liu: Excited to Share that NECTA PANNA-COTA Trial Reaches 100 Patients Enrolled